Article info
PDFOriginal research
Medical crowdfunding in China: empirics and ethics
- Correspondence to Dr Pingyue Jin, School of Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; jinpyue{at}163.com
Citation
Medical crowdfunding in China: empirics and ethics
Publication history
- Received July 10, 2018
- Revised May 14, 2019
- Accepted May 22, 2019
- First published June 19, 2019.
Online issue publication
August 27, 2019
Article Versions
- Previous version (19 June 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- End - of - life decisions as bedside rationing. An ethical analysis of life support restrictions in an Indian neonatal unit
- Funding allocation to surgery in low and middle - income countries: a retrospective analysis of contributions from the USA
- Chinese perspective on end - of - life communication: a systematic review
- Establishment of trauma treatment teams within a regional severe trauma treatment system in China: study protocol for a national cluster - randomised trial
- If I were a rich man could I sell a pancreas? A study in the locus of oppression
- The physician charter on medical professionalism from the Chinese perspective: a comparative analysis
- Highlights from this issue
- Advancing research on the economic value of emergency care
- Operational research to support equitable non-communicable disease policy in low - income and middle - income countries in the sustainable development era: a scoping review
- Using patient - reported outcomes to manage postoperative symptoms in patients with lung cancer: protocol for a multicentre, randomised controlled trial